SAN FRANCISCO--(BUSINESS WIRE)--Loyal, a biotech company pioneering longevity drugs for dogs, today announced that it has successfully completed its Series B funding round, securing $45 million in investment. The round was led by Bain Capital Ventures. This brings total funding raised by Loyal to more than $125 million since its founding in 2019 and includes a $12 million credit facility from Bridge Bank, part of Western Alliance Bank..

旧金山--（商业新闻短讯）--生物技术公司忠诚，一家为狗开发长寿药物的公司，今天宣布，它已成功完成B轮融资，获得4500万美元的投资。本轮谈判由贝恩资本风险投资公司牵头。自2019年成立以来，忠诚银行筹集的资金总额已超过1.25亿美元，其中包括来自Western Alliance Bank旗下Bridge Bank的1200万美元信贷。

Most major existing investors from Loyal’s previous financings – including Khosla Ventures, First Round Capital, Box Group, Collaborative Fund, Quiet Capital, and Todd & Rahul’s Angel Fund – participated in this round. Bain Capital Ventures and Valor Equity Partners are new investors.

Loyal之前融资的大部分主要现有投资者，包括Khosla Ventures、First Round Capital、Box Group、Collaborative Fund、Quiet Capital和Todd&Rahul的天使基金，都参与了这一轮融资。Bain Capital Ventures和Valor Equity Partners是新的投资者。

“This fundraise fuels our efforts to bring to market what we hope will be the first FDA-approved drug to extend healthy lifespan,” said Celine Halioua, Founder and CEO of Loyal. “All of our work is centered on giving dogs longer, healthier lives. I’m proud of the work the team has done to date and we have a very important and challenging vision to realize.

“这次募捐推动了我们的努力，将我们希望的第一种FDA批准的延长健康寿命的药物推向市场，”忠诚的创始人兼首席执行官塞琳·哈利奥阿（Celine Halioua）说。“我们所有的工作都集中在让狗拥有更长、更健康的生活。我为团队迄今为止所做的工作感到骄傲，我们有一个非常重要且具有挑战性的愿景需要实现。

I’m excited to work with our new and existing investors and continue to make FDA-approved dog longevity drugs a reality.”.

我很高兴能与我们新的和现有的投资者合作，继续使FDA批准的狗长寿药成为现实。”。

The Series B funding will support continued development with expected product launch in early 2025, pending FDA approval.

B系列资金将支持持续开发，预计在2025年初推出产品，等待FDA批准。

“Celine and her innovative, passionate, and responsible team at Loyal are making fast progress toward approved longevity medicines,” said Kevin Zhang, Partner at Bain Capital Ventures. “For the 65 million households in America with a dog, Loyal’s promise means longer, healthier dog lives – more priceless memories of excited greetings at the door, games of fetch in the park, and cozy afternoons together on the couch.”.

贝恩资本投资公司合伙人张凯文（KevinZhang）表示：“席琳（Celine）和她的创新、热情和负责的忠诚团队正在朝着批准的长寿药方向取得快速进展。”。“对于美国6500万养狗的家庭来说，忠诚的承诺意味着更长、更健康的狗的生命——更多无价的回忆，如门口兴奋的问候、公园里的接客游戏以及在沙发上度过舒适的下午。”。

This funding follows several significant milestones for the company:

这笔资金遵循了公司的几个重要里程碑：

Earning what Loyal believes to be the FDA’s first-ever formal acceptance that a drug can be developed and approved to extend lifespan. FDA review is being led by the agency’s Center for Veterinary Medicine.

获得忠诚认为是FDA有史以来第一次正式接受可以开发和批准延长寿命的药物。FDA的审查由该机构的兽医中心领导。

Completing the technical effectiveness section of the conditional approval application for LOY-001’s use in large dog lifespan extension.

完成LOY-001用于延长大型犬寿命的有条件批准申请的技术有效性部分。

Launching the STAY study, the pivotal effectiveness study for LOY-002, in development for dog lifespan extension. STAY will include more than 1,000 dogs across over 50 veterinary sites in the United States.

启动STAY研究，这是LOY-002的关键有效性研究，旨在延长狗的寿命。逗留期间将包括美国50多个兽医场的1000多只狗。

Continued progress towards the other FDA dossier approvals necessary for LOY-002 conditional market approval in early 2025.

在2025年初LOY-002有条件市场批准所需的其他FDA档案批准方面继续取得进展。

Strong dog owner and veterinary engagement and interest in Loyal’s products.

强大的狗主人和兽医参与度以及对忠诚产品的兴趣。

Loyal currently has three drugs in development to extend healthy lifespan in dogs. LOY-001 and LOY-003 are designed to extend the healthy lifespan of large-breed dogs, and LOY-002 is designed for senior dogs 14 pounds and over. The company anticipates that LOY-002 will be available in early 2025, pending FDA conditional approval..

忠诚目前正在开发三种药物，以延长狗的健康寿命。LOY-001和LOY-003旨在延长大型犬的健康寿命，而LOY-002是为14磅及以上的老年犬设计的。该公司预计LOY-002将于2025年初上市，等待FDA有条件的批准。

About Loyal

关于忠诚

Loyal is a biotech startup developing the first drugs intended to help dogs live longer, healthier lives. By targeting the underlying mechanisms of aging, Loyal hopes to extend the lifespan of dogs and maintain their quality of life as they age. For more information, please visit loyalfordogs.com.

忠诚是一家生物技术初创公司，开发了第一批旨在帮助狗活得更长、更健康的药物。通过针对衰老的潜在机制，忠诚希望延长狗的寿命，并随着年龄的增长保持其生活质量。有关更多信息，请访问loyalfordogs.com。